Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor
Phase 3positiveZenkudaEyleaPositive
AI Analysis
Summary
Kodiak Sciences announced positive Phase 3 results for Zenkuda, which performed as well as Eylea in wet age-related macular degeneration, potentially positioning it as an Eylea successor. The stock surged on the news.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Zenkuda performed as well as Eylea in wet age-related macular degeneration
Importance:8/10
Sentiment:
0.85
Phase 3 successOphthalmologyCompetitive threat to EyleaStock surge
Related Companies
Read the original article
Published by Endpoints News on September 28, 2026 3:19 PM